Drew Murray
Medical Oncology · Bellingham, WANPI 1295118644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,125 of the $9,959 with a category attached, or 81.6%. It is spread thinly across 41 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,801 and has fallen 96.6% since, to $165 in 2025.
Across 271 payments — averaging $36.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Eisai Inc.$999
- E.r. Squibb & Sons, L.L.C.$752
- Johnson & Johnson$671
- Novo Nordisk$644
- Bristol Myers Squibb$603
- plus $4K from 35 others
Across 18 payments — averaging $10,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$194K
What the payments were for
- Grants$6446%
- Food & beverage$8,12582%
- Education$1,19012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 67 | $2,057 |
| Eisai Inc. | 16 | $999 |
| E.r. Squibb & Sons, L.L.C. | 20 | $752 |
| Johnson & Johnson | 17 | $671 |
| Novo Nordisk | 1 | $644 |
| Bristol Myers Squibb | 9 | $603 |
| Merck | 20 | $394 |
| Incyte Corporation | 12 | $376 |
| Astellas Pharma US Inc | 3 | $313 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $269 |
| Jazz Pharmaceuticals Inc. | 5 | $268 |
| AstraZeneca(2 entities) | 9 | $245 |
| Seagen Inc. | 8 | $204 |
| Sanofi | 10 | $194 |
| Novartis | 11 | $179 |
| Boehringer Ingelheim | 4 | $148 |
| Karyopharm Therapeutics Inc. | 2 | $138 |
| Lilly USA, LLC | 6 | $135 |
| Bayer | 9 | $127 |
| Coherus Oncology, Inc. | 1 | $125 |
| Tempus AI, Inc | 3 | $124 |
| GSK | 1 | $123 |
| Exelixis Inc. | 1 | $122 |
| Beigene USA, Inc. | 1 | $113 |
| Rigel Pharmaceuticals, Inc. | 1 | $88 |
| Intuitive Surgical | 1 | $85 |
| Daiichi Sankyo Inc. | 4 | $64 |
| EMD Serono, Inc. | 3 | $59 |
| Array Biopharma Inc | 3 | $48 |
| Pfizer | 3 | $47 |
| AbbVie | 2 | $46 |
| Clovis Oncology, Inc. | 2 | $30 |
| Foundation Medicine, Inc. | 2 | $25 |
| Verastem, Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $17 |
| EUSA Pharma (US) LLC | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
| Immunomedics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,959 in reported general payments places this provider in the 65th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 61 | $831,152 |
| RevlimidLenalidomide | 48 | $741,676 |
| PomalystPomalidomide | 25 | $580,187 |
| VenclextaVenetoclax | 28 | $473,716 |
| JakafiRuxolitinib Phosphate | 14 | $359,531 |
| ImbruvicaIbrutinib | 20 | $338,448 |
| XtandiEnzalutamide | 27 | $302,987 |
| BrukinsaZanubrutinib | 23 | $292,424 |
| TagrissoOsimertinib Mesylate | 12 | $240,856 |
| Abiraterone Acetate | 82 | $85,570 |
| EliquisApixaban | 74 | $57,806 |
| XareltoRivaroxaban | 25 | $22,735 |
| ZarxioFilgrastim-Sndz | 11 | $12,009 |
| Dexamethasone | 147 | $2,369 |
| Exemestane | 17 | $2,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $603 | $741,67648 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $752 | $580,18725 claims |
| AbbVieVenclexta | $46 | $473,71628 claims |
| Incyte CorporationJakafi | $376 | $359,53114 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $269 | $338,44820 claims |
| Astellas Pharma US IncXtandi | $313 | $302,98727 claims |
| Beigene USA, Inc.Brukinsa | $113 | $292,42423 claims |
| AstraZenecaTagrisso | $245 | $240,85612 claims |
| PfizerEliquis | $47 | $57,80674 claims |
| Johnson & JohnsonXarelto | $671 | $22,73525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Bellingham
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Joseph YeOlympia$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.